Compare Cassava Sciences Inc (FLNA) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Manulife Financial Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Manulife Financial Corporation trades at $43.15 (market cap $70.81B). The key difference: Manulife Financial Corporation is far larger — about 1332.5× Cassava Sciences Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MFC | |
|---|---|---|
Market Cap | $53.14M | $70.81B |
Sector | Health | Financials |
52-Week High | $4.64 | $43.07 |
52-Week Low | $1.09 | $29.90 |
Enterprise Value | -$33.43M | $67.37B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Manulife Financial (MFC) trades at $41.69, up 0.97% on the day and near its 52-week high, reflecting strong technical momentum. The company reported mixed Q1 2026 earnings but has beaten estimates in two of the last three quarters, with revenue growing to $53.01B in 2025. Analyst consensus is bullish with 8 Buy ratings and no Sell recommendations, supported by a solid 12.07% net income margin and 13.14% ROE. Recent news highlights AI advancements and a strong Asia business, though regulatory scrutiny on certain products presents a watch item.
The outlook for MFC is positive, driven by earnings growth in Asia, strategic AI investments, and a robust capital position. Key opportunities include expansion in wealth management and continued dividend returns. Primary risks involve regulatory pressures in Hong Kong, volatility in global wealth segments, and potential margin compression from competitive and macroeconomic forces.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
